Pinealon Research: Neuroprotective Pineal Tripeptide

Pinealon (Glu-Asp-Arg) is a synthetic tripeptide bioregulator derived from the pineal gland, developed by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. As a CNS-targeting member of the Khavinson bioregulator series, Pinealon joins Epithalon (Ala-Glu-Asp-Gly) in addressing pineal and brain biology through the proposed epigenetic bioregulator mechanism.

Structural Context Within the Bioregulator Series

Pinealon (Glu-Asp-Arg) shares the Glu-Asp dipeptide core with Epithalon (Ala-Glu-Asp-Gly) and Cortagen (Ala-Glu-Asp-Pro) — the cortex-targeting bioregulator. This shared Glu-Asp sequence is proposed to constitute a common pharmacophore for CNS bioregulators, with the additional residues providing tissue-targeting specificity. Pinealon's unique Arg C-terminus provides a positively charged guanidinium group that enhances interaction with negatively charged DNA phosphate backbone and anionic chromatin components.

The structural relationship between Pinealon and Epithalon makes them ideal research pair for comparative pharmacology. Both target the pineal/brain system. Both share the Glu-Asp core. The primary structural difference — Pinealon's N-terminus begins with Glu (no Ala) and the fourth residue is Arg (versus Gly in Epithalon) — allows systematic investigation of how N-terminal and C-terminal residue identity affects tissue specificity and potency in the bioregulator series.

Neuroprotection Research

Ischaemia model: Oxygen-glucose deprivation (OGD) is the standard in vitro ischaemia model. Primary cortical neurons (embryonic day 18, culture to DIV14) are transferred to glucose-free ACSF and placed in a hypoxia chamber (95% N2/5% CO2) for 60-90 minutes, then returned to normal culture conditions (reoxygenation). Pinealon pre-treatment (1nM-1µM, 1 hour before OGD) allows assessment of neuroprotective effects. Endpoints at 24 hours after reoxygenation: LDH release (Cytotox-ONE assay), live-dead staining (calcein-AM/ethidium homodimer), caspase-3 activity (fluorogenic substrate Ac-DEVD-AFC), and MAP2 immunofluorescence for neurite morphology.

Oxidative stress: H2O2 (100-500µM) applied to SH-SY5Y neuroblastoma cells or primary neurons for 4 hours. Pinealon pre-treatment (1 hour) at 0.1nM-10µM. Measure cell viability (MTT assay), ROS generation (CM-H2DCFDA fluorescence), mitochondrial membrane potential (JC-1 ratiometric assay), and antioxidant enzyme expression (SOD1, GPX1, catalase by Western blot and RT-PCR).

Beta-amyloid toxicity: Abeta25-35 (a shorter, more easily prepared toxic fragment; or full-length Abeta42 oligomers) applied at 5-10µM to primary hippocampal neurons (DIV14). Pinealon at 0.1nM-1µM added simultaneously or as pre-treatment. Compare with Humanin (the established anti-Abeta neuroprotective MDP) at matched concentrations for benchmarking.

Circadian Biology Research

Pinealon's pineal gland derivation makes it directly relevant to circadian biology research — the pineal gland is the primary melatonin-secreting organ and a key node in the circadian timing system.

AANAT regulation in pinealocytes: Culture rat pinealocytes under controlled light-dark cycles (12:12, lights on at 07:00). During the dark phase (when AANAT is maximally induced), apply Pinealon (1-100nM) and measure AANAT mRNA by RT-PCR at 3-hour intervals. Compare with vehicle and with Epithalon in parallel preparations to characterise whether the Arg versus Gly C-terminal difference affects AANAT regulatory activity.

Melatonin measurement: Direct measurement of melatonin in pinealocyte conditioned medium by ELISA (Melatonin ELISA kit) or LC-MS/MS (more sensitive and specific) provides the functional endpoint for AANAT activity. Plot melatonin production rate versus AANAT mRNA level to determine whether Pinealon effects on AANAT mRNA translate to proportional changes in melatonin synthesis.

Ageing and Neuronal Senescence

The ageing context for Pinealon research follows from the documented age-related decline in pineal function — reduced AANAT activity, reduced melatonin production, altered circadian rhythm amplitude — that parallels broader neurological ageing. Pinealon's proposed epigenetic restorative mechanism suggests that it may partially reverse these age-related functional changes.

Senescence research design: Primary cortical neurons from aged (18-24 month) rodents show elevated SA-beta-galactosidase activity, increased p21 and p16 expression, and reduced neurotrophic factor (BDNF, NGF) expression compared to young adult neurons. Pinealon treatment (1nM-100nM) of aged neuron cultures for 72 hours, followed by SA-beta-gal staining (X-gal, pH 6.0), p21/p16 Western blot, and BDNF ELISA, allows assessment of whether the bioregulator modulates the senescent phenotype in aged CNS neurons.

Key Published Research

• Khavinson VKh, Grigoriev EI. "Peptide bioregulators for correcting age-related pineal and brain function." Advances in Gerontology, 2005.
• Stavchansky VV, et al. "Effects of peptide bioregulators on expression of genes regulating neuro- and angiogenesis in rat brain under ischemic conditions." Doklady Biochemistry and Biophysics, 2015.
• Khavinson V, et al. "Short peptides stimulate genome expression." Advances in Gerontology, 2013.

View Pinealon →

For laboratory and analytical research purposes only. Not for human or veterinary use.